Antidepressants vs Therapy: What Meta-Analyses Really Show

If you've been diagnosed with depression or anxiety, one of the first questions your clinician will likely ask is: Would you prefer medication, therapy, or both? It's a deceptively simple question with enormous implications for your time, finances, side effects, and long-term wellbeing. The honest answer about antidepressants vs therapy — the one most patients rarely hear — is that decades of meta-analytic research paint a far more nuanced picture than the marketing of either pharmaceuticals or psychotherapy would suggest.

This article moves past the ideological debate and walks through what large-scale meta-analyses actually show about antidepressants versus psychotherapy for common mental health conditions. We'll examine effect sizes, relapse rates, dropout rates, patient preference, and the specific situations where one approach clearly outperforms the other. The goal isn't to talk you into or out of any treatment — it's to help you and your prescriber or therapist make an informed, values-aligned choice.

Key Takeaways

• Short-term efficacy is roughly equivalent between antidepressants and evidence-based psychotherapies (CBT, IPT, behavioral activation) for major depression.
• Psychotherapy tends to produce more durable results, with lower relapse rates once treatment ends compared to discontinued medication.
• For anxiety disorders, OCD, and PTSD, meta-analyses favor psychotherapy — particularly exposure-based and trauma-focused approaches.
• Combined treatment outperforms either alone for severe, chronic, or recurrent depression by roughly 15–20 percentage points in remission.
• Patient preference significantly predicts outcome — around 75% of patients prefer therapy, and honoring that preference improves adherence and response.
• Antidepressants carry meaningful side effects: 40–55% report sexual dysfunction, and ~40% experience discontinuation syndrome when stopping.

The Big Picture: What Meta-Analyses Are and Why They Matter

Meta-analyses pool results across many individual studies to generate a more statistically powerful estimate of a treatment's true effect. For depression and anxiety, this method cuts through the noise of any single trial and reveals patterns that inform real clinical decisions.

What is a meta-analysis in mental health research?

A meta-analysis is a statistical synthesis of multiple studies addressing the same clinical question. For depression and anxiety specifically, we now have dozens of large meta-analyses — some analyzing over 500 randomized trials and hundreds of thousands of patients. This is important because a single study can be biased by industry funding, small sample sizes, or selective outcome reporting. Meta-analyses, when done well, wash out much of that noise [Cochrane, 2023].

How are treatment effects measured?

Effect sizes in these studies are usually reported as standardized mean differences (SMDs) or Hedges' g. As a rough rule of thumb: 0.2 is small, 0.5 is moderate, and 0.8 is large. Placebo response in depression trials is famously large — around SMD 1.2 in absolute terms — which is why the additional benefit of active treatment often looks modest [Cipriani et al., 2018].

Why should patients care about effect sizes?

Because clinicians and marketing materials often frame treatments in absolute terms ("proven to work"), while the reality is a continuum of probability. Understanding effect size helps you weigh expected benefit against side effects, cost, and time — the actual trade-offs of treatment.

Head-to-Head: Antidepressants vs Therapy for Depression

For major depressive disorder, meta-analyses consistently find that antidepressants and evidence-based psychotherapies produce roughly equivalent short-term symptom reduction. The bigger differences emerge in long-term durability, side effect profile, and how each treatment interacts with severity.

Is short-term efficacy really equivalent?

The landmark meta-analysis by Cuijpers and colleagues, updated repeatedly over the past 15 years, consistently finds that antidepressants and evidence-based psychotherapies (primarily CBT, interpersonal therapy, and behavioral activation) produce roughly equivalent short-term reductions in depressive symptoms in adults with major depressive disorder [Cuijpers et al., 2020]. Combined treatment tends to outperform either alone, with an added effect size of about 0.30 over monotherapy [Cuijpers et al., 2020].

The largest network meta-analysis of antidepressants — the Cipriani study covering 522 trials and 116,477 participants — found all 21 antidepressants tested were more effective than placebo, with effect sizes ranging from 0.30 to 0.55 (small to moderate) [Cipriani et al., 2018]. Psychotherapy meta-analyses land in a similar range, though adjusted effect sizes may be closer to 0.30 once publication bias and risk-of-bias corrections are applied [Cuijpers et al., 2019].

Do long-term outcomes favor psychotherapy?

Yes. Once treatment ends, patients who received psychotherapy (particularly CBT) tend to maintain gains longer and relapse less than those who discontinue antidepressants. A meta-analysis in JAMA Psychiatry found that CBT after antidepressant response reduced relapse risk by approximately 21% compared to antidepressant continuation alone [Kuyken et al., 2016]. Another analysis of long-term follow-up data suggested that patients receiving CBT alone had lower relapse rates at 12 months than those on continued medication [Cuijpers et al., 2013].

The clinical implication: antidepressants work while you take them; therapy tends to build durable skills that continue paying dividends after treatment ends. This doesn't make medication inferior — it just reframes what each intervention is really doing.

Does severity change the equation?

You may have read that antidepressants work best for severe depression and no better than placebo for mild depression. This claim, popularized by a 2010 JAMA meta-analysis, has since been contested. More recent meta-analyses suggest antidepressants do provide benefit across severity levels, though the added benefit over placebo is somewhat larger in severe cases [Furukawa et al., 2018]. Psychotherapy, meanwhile, shows robust effects across mild, moderate, and severe presentations [Weitz et al., 2015].

Anxiety Disorders: A Slightly Different Picture

For anxiety, meta-analyses tilt more clearly toward psychotherapy. Exposure-based and trauma-focused interventions produce larger, more durable effects than medication, particularly once placebo response is properly accounted for.

What does the evidence say for generalized anxiety and panic?

For generalized anxiety disorder, panic disorder, social anxiety disorder, and PTSD, meta-analyses generally find psychotherapy — particularly CBT and exposure-based therapies — produces larger and more durable effects than medication [Bandelow et al., 2015]. A comprehensive meta-analysis of anxiety treatments across disorders reported pre-post effect sizes of approximately 2.02 for medications and 1.22 for psychotherapies, but medication effect sizes shrink dramatically when placebo is properly controlled [Bandelow et al., 2015].

Why is trauma-focused therapy first-line for PTSD?

For PTSD specifically, the American Psychological Association's clinical practice guideline gives its strongest recommendation to trauma-focused psychotherapies (cognitive processing therapy, prolonged exposure, EMDR) and only a conditional recommendation to SSRIs and SNRIs [APA, 2017]. This is not because medications don't work — they do — but because trauma-focused therapies produce larger effects with more durable results.

What about OCD?

For OCD, meta-analyses consistently find that exposure and response prevention (ERP) outperforms SSRIs for symptom reduction, though combined treatment is often recommended for severe cases [Skapinakis et al., 2016]. Approaches like ACT for Anxiety Disorders also show promise for worry and avoidance behaviors that overlap with OCD presentations.

Where Antidepressants Have a Clear Edge

Antidepressants remain the treatment of choice in specific scenarios where biological stabilization, speed, or accessibility outweighs therapy's durability advantage.

When should medication be first-line?

Meta-analyses reveal several scenarios where medication is likely the better first-line choice:

• Severe or melancholic depression with vegetative symptoms. When a person cannot get out of bed, cannot concentrate enough to engage in therapy, or is experiencing psychotic features, antidepressants (sometimes combined with antipsychotics) work faster and more reliably [NICE, 2022].
• Bipolar depression. Antidepressant monotherapy is generally contraindicated, but mood stabilizers and second-generation antipsychotics have strong evidence [Yatham et al., 2018]. Psychotherapy is adjunctive here, not primary.
• Recurrent depression with a strong biological signature. Patients with three or more prior episodes benefit substantially from maintenance pharmacotherapy in preventing recurrence [Geddes et al., 2003].
• When therapy is inaccessible. Medication requires a 15-minute prescriber visit; therapy requires weekly hour-long sessions with a scarce, expensive workforce. In much of the world, medication is simply the only realistic option [WHO, 2022].
• Rapid symptom relief in crisis. While antidepressants themselves take 4–6 weeks to work, medication management can incorporate faster-acting options in specific situations.

For a deeper primer on drug classes, mechanisms, and options, see our full guide to Antidepressants Explained: SSRIs, SNRIs & Atypicals Guide 2025.

Where Psychotherapy Has a Clear Edge

Psychotherapy shines when durability, skill-building, or avoiding medication exposure matters most — including anxiety disorders, perinatal depression, and youth presentations.

Which conditions clearly favor therapy?

Meta-analyses identify populations and conditions where therapy should be considered first:

• Mild to moderate depression in patients who prefer non-medication approaches. Preference itself predicts outcomes; patients who receive their preferred treatment have better adherence and response [Swift & Callahan, 2009].
• Anxiety disorders, especially specific phobias, social anxiety, and OCD. Exposure-based interventions produce durable neurobiological change and outperform medication in long-term follow-up [Bandelow et al., 2015].
• PTSD. Trauma-focused therapies are the frontline recommendation from the APA, VA/DoD guidelines, and WHO [APA, 2017; VA/DoD, 2023].
• Personality-related distress or complex trauma. Medication doesn't treat maladaptive patterns of relating; DBT, schema therapy, and mentalization-based treatment do [NICE, 2009].
• Pregnancy and breastfeeding. Many patients prefer to avoid antidepressant exposure, and meta-analyses support CBT and interpersonal therapy for perinatal depression [Sockol, 2015].
• Children and adolescents. Guidelines generally recommend psychotherapy as the first-line intervention for mild-to-moderate youth depression, with medication reserved for moderate-to-severe cases or after inadequate response to therapy [NICE, 2019].

Combined Treatment: When 1 + 1 > 2

Combining medication and psychotherapy consistently outperforms either alone for the most difficult clinical presentations. The magnitude of added benefit depends on severity, chronicity, and comorbidity.

Who benefits most from combined treatment?

Multiple meta-analyses suggest that combining medication and psychotherapy outperforms either alone, particularly for chronic, severe, or recurrent depression [Cuijpers et al., 2020]. The largest benefits appear when:

• Depression is severe or has been present for over two years
• Patients have a history of childhood trauma
• There are co-occurring anxiety or substance use disorders
• Prior single-modality treatment has failed

For example, the STAR*D and other large real-world studies suggest that combining CBT with an antidepressant can achieve remission rates approximately 15–20 percentage points higher than medication alone in treatment-resistant cases [Wiles et al., 2016]. If you're weighing therapy modalities specifically for depression, our comparison of Behavioral Activation vs Antidepressants offers deeper detail on one of the most effective — and underused — options.

The Dropout and Side Effect Problem

Efficacy is only half the equation. Whether patients can tolerate and stick with a treatment often determines real-world outcomes more than trial data suggests.

How many people quit antidepressants due to side effects?

Efficacy is only half the story. Acceptability — measured by how many people stop treatment — is arguably just as important. Meta-analyses consistently find:

• Antidepressant dropout rates in trials average around 20–30%, driven largely by side effects such as sexual dysfunction, weight gain, GI symptoms, and emotional blunting [Cipriani et al., 2018].
• Psychotherapy dropout rates are similar in trials but may be higher in real-world settings due to logistical and financial barriers [Swift & Greenberg, 2012].
• Roughly 40–55% of people on SSRIs report sexual side effects [Cleveland Clinic, 2023].
• Discontinuation syndrome — sometimes severe and prolonged — occurs in an estimated 40% of people stopping antidepressants, with about half describing it as severe [Davies & Read, 2019].

Does therapy have side effects too?

Yes, though of a different kind. Therapy carries risks like emotional discomfort during exposure work, temporary symptom worsening in trauma processing, and the significant time and financial cost. But it doesn't involve the pharmacological withdrawal, weight changes, or intimate side effects that lead many people to discontinue medication.

Patient Preference: The Overlooked Predictor

Preference is not a soft variable — it's one of the strongest predictors of treatment outcome across the meta-analytic literature. Yet it's routinely overridden by access constraints and prescriber habit.

How much does preference actually influence outcomes?

Perhaps the most under-discussed finding across meta-analyses is that patient preference substantially predicts outcome. A meta-analysis of 34 studies found that patients who received their preferred treatment were significantly less likely to drop out and more likely to improve [Swift et al., 2018]. When surveyed, roughly 75% of patients with depression express a preference for psychotherapy over medication [McHugh et al., 2013] — a preference that is often not honored due to access constraints.

What does this mean for shared decision-making?

This has direct implications for clinical practice. If two treatments are roughly equivalent in short-term efficacy but a patient strongly prefers one, the choice is clear. Coercing someone into a treatment they distrust is not just ethically dubious; it's clinically counterproductive.

What About Novel Treatments?

The comparison isn't only SSRIs versus CBT anymore. Newer psychotherapies, digital interventions, and rapid-acting agents like ketamine are expanding — and complicating — the treatment landscape.

Which newer therapies have meta-analytic support?

Meta-analyses increasingly cover:

• Behavioral activation (BA): As effective as CBT and antidepressants for depression, with strong evidence of durability [Ekers et al., 2014]. Often cheaper and easier to deliver than full CBT.
• Acceptance and Commitment Therapy (ACT): Growing evidence base for depression, anxiety, chronic pain, and OCD, with effect sizes comparable to CBT [A-Tjak et al., 2015]. Our overview of Acceptance and Commitment Therapy Research: A Decade On reviews the current state of evidence.
• Mindfulness-Based Cognitive Therapy (MBCT): Meta-analyses show MBCT reduces depression relapse by roughly 30% in patients with three or more prior episodes — comparable to maintenance antidepressants [Kuyken et al., 2016].
• Ketamine and esketamine: Rapid onset for treatment-resistant depression; effect sizes larger than SSRIs in the short term but questions remain about durability and long-term safety [NIMH, 2023].
• Digital and internet-delivered CBT (iCBT): Meta-analyses find effect sizes comparable to face-to-face therapy for mild-to-moderate depression and anxiety, with major implications for access [Andrews et al., 2018].

A Framework for Choosing

Given the evidence, here's a practical decision framework grounded in current meta-analytic findings and clinical guidelines. Use it as a starting point for a conversation with your prescriber or therapist — not a substitute for one.

When should you start with psychotherapy?

• Your depression or anxiety is mild to moderate
• You have a specific anxiety disorder, phobia, OCD, or PTSD
• You have a history of medication intolerance or strong side effect concerns
• You're pregnant, breastfeeding, or planning conception
• Your distress is linked to trauma, relationships, identity, or life transitions
• You value skill-building and long-term relapse prevention
• You have access to a qualified therapist and can commit to weekly sessions

When should you start with medication?

• Symptoms are severe enough that you can't engage in therapy (can't concentrate, can't get out of bed, can't function)
• You have melancholic, psychotic, or bipolar features
• You've had multiple prior depressive episodes
• Therapy is inaccessible or unaffordable in your area
• You've tried psychotherapy without adequate response
• You prefer medication after weighing the trade-offs

When is combined treatment the best call?

• Depression is severe, chronic, or recurrent
• You have significant comorbidity (anxiety + depression, substance use + PTSD)
• Prior monotherapy has failed
• Childhood trauma is a significant contributor

Questions to Ask Your Prescriber or Therapist

Whether you land on medication, therapy, or both, the quality of your conversation with your clinician matters enormously. These questions surface trade-offs that generic recommendations gloss over.

1. What's the evidence base for this specific treatment for my specific condition? A generic "antidepressants work for depression" answer isn't enough.
2. How long until I know if it's working? Antidepressants: 4–6 weeks. Therapy: often 6–12 sessions to assess response.
3. What are the realistic side effects or discomforts? Ask specifically about sexual function, weight, emotional blunting, and discontinuation for medication; about exposure discomfort and homework demands for therapy.
4. What's the plan if this doesn't work? Good clinicians have a decision tree in mind before starting.
5. How will we taper or end treatment safely? Especially important for antidepressants.
6. Does this align with my values and life circumstances? A treatment you can't sustain is not a treatment.

What Meta-Analyses Cannot Tell You

Meta-analyses summarize averages across populations. They cannot tell you what will work for the specific person you are, with your history, genetics, values, and circumstances.

What are the limits of pooled evidence?

For all their statistical power, meta-analyses have real limitations. They average across heterogeneous populations, may under-represent minoritized groups, often exclude patients with comorbidities, and can obscure meaningful individual differences. Your genetics, trauma history, values, culture, and preferences are not captured in a forest plot.

This means the meta-analytic evidence is a starting point — not a verdict. Two people with the same diagnosis and the same severity score may need very different treatments. And what works today may need to be revised in six months as your life, symptoms, and goals evolve.

The Bottom Line

The most honest reading of the meta-analytic literature is this: for common depression and anxiety, antidepressants and evidence-based psychotherapies produce roughly comparable short-term benefit, but they achieve it differently and leave different footprints. Medication provides a biological floor that lifts symptoms while it's taken. Therapy builds skills, insight, and behavioral patterns that tend to outlast treatment itself. Combined treatment is often superior for severe or chronic presentations. Preference matters enormously. Side effects and access matter enormously. And for anxiety disorders and PTSD specifically, the evidence tilts meaningfully toward therapy.

The choice is rarely medication versus therapy in an absolute sense. It's more often: medication now to stabilize while I start therapy, or therapy first with medication held in reserve, or both together for a season and then a considered taper. Wherever you land, the goal is the same — reducing suffering, restoring function, and building a life that feels worth living. Meta-analyses can inform that path. Only you and a trusted clinician can walk it.

If you are in crisis or having thoughts of suicide, please contact a local emergency service, the 988 Suicide and Crisis Lifeline (US), or your country's equivalent. Meta-analyses take months to read. Help is available now.

Frequently Asked Questions

Are antidepressants or therapy more effective for depression?

For mild-to-moderate major depression, meta-analyses show antidepressants and evidence-based psychotherapies (like CBT and behavioral activation) are roughly equivalent in short-term symptom reduction. However, therapy tends to produce more durable results, with lower relapse rates after treatment ends. For severe or recurrent depression, combined treatment usually outperforms either alone.

Why do so many patients prefer therapy over medication?

Surveys find approximately 75% of patients with depression prefer psychotherapy to medication. Reasons include concerns about side effects (sexual dysfunction, weight gain, emotional blunting), fear of dependency or discontinuation syndrome, and a desire to address root causes rather than manage symptoms. Honoring patient preference improves both adherence and outcomes.

How long do antidepressants take to work?

Most antidepressants require 4–6 weeks to reach full therapeutic effect, though some people notice partial benefit within 2 weeks. If there's no meaningful response after 6–8 weeks at a therapeutic dose, clinicians typically consider dose adjustment, switching agents, augmenting with therapy, or adding a second medication.

Which is better for anxiety — therapy or medication?

Meta-analyses generally favor psychotherapy — particularly CBT and exposure-based therapies — for anxiety disorders. Exposure work produces durable neurobiological changes and outperforms medication in long-term follow-up. For PTSD specifically, trauma-focused therapies (CPT, PE, EMDR) receive the strongest recommendation from the APA, VA/DoD, and WHO guidelines.

Is it safe to stop antidepressants once I feel better?

Stopping antidepressants requires a slow, supervised taper. Approximately 40% of people experience discontinuation syndrome — symptoms like dizziness, nausea, brain zaps, anxiety, and mood changes — with about half describing it as severe. Guidelines increasingly recommend hyperbolic tapering over months, sometimes years, rather than the traditional weeks-long approach.

Can therapy alone treat severe depression?

Psychotherapy shows robust effects across mild, moderate, and severe depression. However, when depression is severe enough that a person cannot concentrate, get out of bed, or engage with a therapist, medication is often needed first to enable meaningful therapy participation. For melancholic, psychotic, or bipolar features, medication is essential.

Does combining medication and therapy really work better?

References

A-Tjak, J. G. L., et al. (2015). A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. https://pubmed.ncbi.nlm.nih.gov/25547522/

American Psychological Association (2017). Clinical practice guideline for the treatment of PTSD in adults. https://www.apa.org/ptsd-guideline

Andrews, G., et al. (2018). Computer therapy for the anxiety and depression disorders is effective, acceptable and practical health care: An updated meta-analysis. https://pubmed.ncbi.nlm.nih.gov/29422409/

Bandelow, B., et al. (2015). Efficacy of treatments for anxiety disorders: A meta-analysis. https://pubmed.ncbi.nlm.nih.gov/25932596/

Cipriani, A., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext

Cleveland Clinic (2023). SSRI-induced sexual dysfunction. https://my.clevelandclinic.org/health/diseases/24506-antidepressants-and-sex-drive

Cochrane Collaboration (2023). About Cochrane reviews. https://www.cochrane.org/about-us/our-work

Cuijpers, P., et al. (2013). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders. World Psychiatry. https://pubmed.ncbi.nlm.nih.gov/23737408/

Cuijpers, P., et al. (2019). Was Eysenck right after all? A reassessment of the effects of psychotherapy for adult depression. Epidemiology and Psychiatric Sciences. https://pubmed.ncbi.nlm.nih.gov/29769158/

Cuijpers, P., et al. (2020). A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. https://pubmed.ncbi.nlm.nih.gov/31922679/

Davies, J., & Read, J. (2019). A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors. https://pubmed.ncbi.nlm.nih.gov/30292574/

Ekers, D., et al. (2014). Behavioural activation for depression: An update of meta-analysis of effectiveness and sub group analysis. PLoS ONE. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0100100

Furukawa, T. A., et al. (2018). Initial severity of depression and efficacy of new generation antidepressants. Acta Psychiatrica Scandinavica. https://pubmed.ncbi.nlm.nih.gov/29532466/

Geddes, J. R., et al. (2003). Relapse prevention with antidepressant drug treatment in depressive disorders. The Lancet. https://pubmed.ncbi.nlm.nih.gov/12615259/

Kuyken, W., et al. (2016). Efficacy of mindfulness-based cognitive therapy in prevention of depressive relapse. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2517515

McHugh, R. K., et al. (2013). Patient preference for psychological vs pharmacologic treatment of psychiatric disorders. Journal of Clinical Psychiatry. https://pubmed.ncbi.nlm.nih.gov/23842011/

NICE (2009). Borderline personality disorder: Recognition and management. https://www.nice.org.uk/guidance/cg78

NICE (2019). Depression in children and young people. https://www.nice.org.uk/guidance/ng134

NICE (2022). Depression in adults: Treatment and management. https://www.nice.org.uk/guidance/ng222

NIMH (2023). Ketamine for treatment-resistant depression. https://www.nimh.nih.gov/news/science-news/2019/ketamine-lifts-depression-via-a-byproduct-of-its-metabolism

Skapinakis, P., et al. (2016). Pharmacological and psychotherapeutic interventions for management of OCD in adults. The Lancet Psychiatry. https://pubmed.ncbi.nlm.nih.gov/27476680/

Sockol, L. E. (2015). A systematic review of the efficacy of cognitive behavioral therapy for perinatal depression. Journal of Affective Disorders. https://pubmed.ncbi.nlm.nih.gov/25795535/

Swift, J. K., & Callahan, J. L. (2009). The impact of client treatment preferences on outcome: A meta-analysis. Journal of Clinical Psychology. https://pubmed.ncbi.nlm.nih.gov/19226606/

Swift, J. K., & Greenberg, R. P. (2012). Premature discontinuation in adult psychotherapy: A meta-analysis. Journal of Consulting and Clinical Psychology. https://pubmed.ncbi.nlm.nih.gov/22506792/

Swift, J. K., et al. (2018). Treatment refusal and premature termination in psychotherapy, pharmacotherapy, and their combination. Psychotherapy. https://pubmed.ncbi.nlm.nih.gov/29565626/

VA/DoD (2023). Clinical practice guideline for the management of PTSD and acute stress disorder. https://www.healthquality.va.gov/guidelines/MH/ptsd/

Weitz, E. S., et al. (2015). Baseline depression severity as moderator of depression outcomes between CBT vs pharmacotherapy. JAMA Psychiatry. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2381544

WHO (2022). World mental health report: Transforming mental health for all. https://www.who.int/publications/i/item/9789240049338

Wiles, N., et al. (2016). Long-term effectiveness and cost-effectiveness of CBT as an adjunct to pharmacotherapy for treatment-resistant depression (CoBalT). Health Technology Assessment. https://pubmed.ncbi.nlm.nih.gov/26910481/

Yatham, L. N., et al. (2018). CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders. https://pubmed.ncbi.nlm.nih.gov/29536616/